I was surprised to see that as of 3/13/15 settlement date, the Short Interest on OMER increased by nearly 2 million shares to 8,159,349. This information is available at: www.nasdaq.com/symbol/omer/short-interest
While there is precious little that anyone can do to force shorts to cover their position, depending on which brokerage company the shorters use they may be paying interest on their balances. This adds up after a while. At some point these shares will have to be purchased.
Generally, only shares in margin accounts can be "loaned" to shorters. If anyone has OMER shares in a margin account, advising your broker to switch them to a cash account would eventually reduce the availability for shorters to borrow shares, and thus place some pressure against them.
Thank you to all the posters of real information!
If you look at the forward revenue estimates there is no doubt that this company is moving very rapidly towards pofitability
Sentiment: Strong Buy
Zacks: Omeros Receives Average Rating of “Strong Buy” from Analysts (NASDAQ:OMER)
March 24th, 2015
Omeros (NASDAQ:OMER) has earned an average broker rating score of 1.20 (Strong Buy) from the five analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and four have given a strong buy rating to the company. Omeros’ rating score has improved by 20% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Analysts have set a 1-year consensus price target of $38.50 for the company and are forecasting that the company will post ($0.66) EPS for the current quarter, according to Zacks. Zacks has also given Omeros an industry rank of 112 out of 265 based on the ratings given to related companies.
i get it, it's not the end of the world - i would put it back up, but dont think msg brd allows me to. have a wonderful day/life.
I want you not to delete your posts. When you delete your posts all the other replies to your post are also deleted. So all the other posts about Q2 sales between myself, eviradr, agutexas, and sisyphus22 are now also deleted. If you had really read my post you would understand that I am all for changing minds, but not deleting posts.
Ask yourself if you would spend time replying to some one if you know that your posts were going to be deleted.
i stated i was sorry, what #$%$ more do you want ? geez, it was before i listened to the call - can one not change his mind ? also, would never really take to the bank anything ever says on here, will do my own dd.
Any poster that deletes their topics after facts come out, to rewrite history, can't be fully trusted. Johnny's "not impressed from the CC" topic had other posts with useful opinions, that are now lost because Johnny now thinks he made a mistake with his post. It is perfectly normal to be wrong or change opinions after more info or thought, it is called learning. To rewrite history is just wrong, unless you are trying to be a politician.
Demopolous is the real deal. The main reason I'm so heavily invested in this company. This guy has the smarts and the drive to build this company into something
i am sorry, i made that statement BEFORE actually listening to the call last night. i like what i heard, especially ALL the analysts questions and greg demopulos speaks well, i wish he would speak more often.
johnny - does that mean you are on board now, too - you said you weren't impressed with the CC. I'll admit it wasn't anything to get the juices flowing and waiting another quarter to get any real data on how the launch of Omidria will go is frustrating, but there were positive comments/vibes for much of the pipeline. I think this is one you keep for the long haul, rather than bail out on any positive Omidria traction. Something tells me the value of the rest of the pipeline will eclipse Omidria's value by multiples?
Their sales figures are low for a bunch of pencil pushers. I do use analyst guidance where they are other FDA approved drugs in the field or it is a drug taken by a patient over a period of time.
Will use a couple of examples why their sales figures are low.
First, peak sales by most analyst are around 500-700 mil. With worldwide procedures to be around 25 mil in a couple of years if we used a $200 selling price for omidria the total market would be 5 billion. Why would they put market penetration at around 10% for the only approved drug? There will be over 2mil Medicare and or Medicaid procedures for the drug this year and next year. The Medicare and Medicaid procedures alone can top 1 billion in sales just in the US.
Second, physician are professional and follow a standard. Per my DD and understanding on compounds, they are used when there is no FDA approved drug on the market or when the FDA approved drug may harm the patient. Omidria is an FDA approved drug and by default good physician will use the drug. There is no other FDA approved drug that omidria is trying to take market share from (this is where I will use analyst guidance). Physician will not have a concern about the long term effects of using a omidira over a period of time since the drug a one procedure drug.
That is why I think the pencil pushers got the peak sales and annual sales wrong for omidira. I will not have access to the internet for a week so if there is another question it will be around next Thursday before I can comment.
That is all positive. To enhance the credibility of your comment, it would be nice to read "were" instead of "where".